Barr and Bayer Sign Supply and Licensing Agreements for Launch of Generic Yasmin(R) and Yaz(R) Oral Cont...(teproduct development activities in the ...),Health

Date:6/23/2008

te product development activities in the timeframes and for the costs we expect; market and customer acceptance and demand for our pharmaceutical products; our dependence on revenues from significant customers; reimbursement policies of third party payors; our dependence on revenues from significant products; the use of estimates in the preparation of our financial statements and our forecasts; the impact of competitive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment in the markets where we operate; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies (such as PLIVA d.d.) and products we acquire and implementing our new SAP enterprise resource planning system; fluctuations in operating results, including the effects on such results from spending for research and development, sales and marketing activities and patent challenge activities; the inherent uncertainty associated with financial projections; our expansion into international markets through our PLIVA acquisition, and the resulting currency, governmental, regulatory and other risks involved with international operations; our ability to service our significantly increased debt obligations as a result of the PLIVA acquisition; changes in generally accepted accounting principles; and other risks detailed in our SEC filings, including in our Annual Report on Form 10-K for the year ended December 31, 2007.

The forward-looking statements contained in this press release speak only as of the date the statement was made. The Company undertakes no obligation (nor does it intend) to p
'/>"/>

SOURCE Barr Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Statement From Bayer(R) Aspirin Regarding the American Medical Associations New Aspirin Policy Resolution
2. Bayer Announces Availability of Reformulated Liquid Leukine(R)
3. ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer Healthcare
4. United Nations Environment Programme and Bayer Corporation Announce North American Winners of International Childrens Painting Competition
5. Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
6. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
7. Bayer to Receive Two Top National Awards for Its Science Education, Science Literacy Work
8. Bayer HealthCare and Juvaris BioTherapeutics Announce Major Licensing Agreement
9. 60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG
10. Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation
11. Bayer Corporation Renames Its U.S. Foundation, Refocuses Charitable Giving Areas